Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies to treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the Saber Delivery System (a patented and versatile depot injectable useful for proteins, peptides and small molecule delivery), the Oradur sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the Transdur transdermal patch technology, the Durin Biodegradable Implant (drug-loaded implant system) and the Microdur Biodegradable Microparticulates (microspheres injectable system). DRRX also partners with pharmaceutical and biotechnology companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DRRX has seven disclosed on-going development programs of which six are in collaboration with pharmaceutical partners. DRRX is also developing DUR-928, an endogenous orally bioavailable small molecule that modulates the activity of various nuclear receptors that play an important regulatory role in lipid homeostasis, inflammation and cell survival.